LifeMD, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 52/100
What the filing says
LifeMD reported Q2 2026 revenue of $47.3M (within $47–50M guidance), adjusted EBITDA loss of $3.5M, and 356,000 total active subscribers (+20% YoY). The company cut full-year 2026 guidance substantially: revenue from $220–230M to $205.5–212.5M (downward $14.5–24.5M midpoint) and adjusted EBITDA from +$12–17M to −$6M to breakeven (downward ~$18M midpoint), citing heavier-than-expected impact from transition to branded GLP-1 therapies and lower upfront revenue. Cash remains at $25.1M with no debt and $30M undrawn credit line.
Why this rating
Guidance cut of ~$18M adjusted EBITDA (~3.5% of market cap) plus revenue miss relative to prior expectations is material but partly telegraphed. Company claims path to profitability H2 2026; solvency not threatened. Moderate negative momentum shift.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.